Mersana Therapeutics, Inc.

NasdaqGS:MRSN 株式レポート

時価総額：US$226.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Mersana Therapeutics マネジメント

マネジメント 基準チェック /24

Mersana Therapeutics'の CEO はMarty Huberで、 Sep2023年に任命され、 の在任期間は 4.42年です。 の年間総報酬は$ 3.04Mで、 6.4%給与と93.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.095%を直接所有しており、その価値は$ 245.46K 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と7.3年です。

主要情報

Marty Huber

最高経営責任者

US$3.0m

報酬総額

CEO給与比率6.4%
CEO在任期間less than a year
CEOの所有権0.09%
経営陣の平均在職期間4.1yrs
取締役会の平均在任期間7.3yrs

経営陣の近況

Recent updates

Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Aug 15
Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Aug 13
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Jun 19
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mersana Therapeutics: On Hold While Waiting For Any Positive News

May 15

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Apr 25
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Feb 27
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Oct 14
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Jun 09
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Feb 22
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana gains as FDA grants fast track status for breast cancer drug

Sep 12

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Aug 15

Taking The Measure Of Mersana Therapeutics

Jan 10

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

Jun 29

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05
It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29
Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Bain Capital discloses 4.8% stake in Mersana Therapeutics

Jan 13

Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst

Jan 11

Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study

Jan 05

CEO報酬分析

Mersana Therapeutics の収益と比較して、Marty Huber の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$105m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$3mUS$194k

-US$172m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$215m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022US$163kn/a

-US$204m

Sep 30 2022n/an/a

-US$208m

Jun 30 2022n/an/a

-US$194m

Mar 31 2022n/an/a

-US$183m

Dec 31 2021US$290kn/a

-US$170m

Sep 30 2021n/an/a

-US$150m

Jun 30 2021n/an/a

-US$127m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$88m

報酬と市場: Martyの 総報酬 ($USD 3.04M ) は、 US市場 ($USD 1.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Martyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Marty Huber (63 yo)

less than a year

在職期間

US$3,044,085

報酬

Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Martin Huber
Presidentless than a yearUS$3.04m0.095%
$ 215.2k
Brian DeSchuytner
Senior VP5.2yrsUS$1.74m0.044%
$ 100.9k
Timothy Lowinger
Senior VP and Chief Science & Technology Officer16.6yrsUS$1.69m0.16%
$ 368.8k
Alejandra Carvajal
Senior VP3.4yrsUS$1.61m0.022%
$ 50.7k
Mohan Bala
Senior VP & Chief Development Officer2.9yrsUS$1.58m0.011%
$ 26.0k
Mikhail Papisov
Co-Founderno dataデータなしデータなし
Ashish Mandelia
Chief Accounting Officer5yrsデータなし0.021%
$ 48.0k
Jason Fredette
Senior Vice President of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Chuck Miller
Senior Vice President of Regulatory Affairs4.1yrsデータなしデータなし
Marc Damelin
Exe. Director and Head of Biologyno dataデータなしデータなし

4.1yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: MRSNの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Martin Huber
President4.4yrsUS$3.04m0.095%
$ 215.2k
David Mott
Independent Chairman12.2yrsUS$329.93k0.48%
$ 1.1m
Peter Kiener
Member of the Scientific Advisory Boardno dataデータなしデータなし
Lawrence Alleva
Independent Director7yrsUS$308.93k0.0017%
$ 3.9k
Willard Dere
Independent Director6.5yrsUS$305.43k0.020%
$ 45.7k
Kristen Hege
Independent Director8.1yrsUS$293.43k0%
$ 0
Anna Protopapas
Director9.5yrsUS$4.65m0.34%
$ 778.9k
Andrew A. Hack
Independent Director7.7yrsUS$297.43k0%
$ 0
Misti Ushio
Board Observerno dataデータなしデータなし
Howard Burris
Member of the Scientific Advisory Boardno dataデータなしデータなし
Allene Diaz
Independent Director3.5yrsUS$294.93k0%
$ 0
K. Wittrup
Member of Scientific Advisory Boardno dataデータなしデータなし

7.3yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: MRSNの 取締役会 は 経験豊富 であると考えられます ( 7.1年の平均在任期間)。